JDS and Synthon Enter Co-Promotion for Lithobid

JDS Pharmaceuticals and Synthon Pharmaceuticals have entered into a co-promotion agreement for Lithobid (lithium carbonate), a leading brand of twice daily lithium carbonate for the treatment of bipolar disorder. Synthon will co-promote Lithobid through its sales force of approximately 50 sales representatives to high volume prescribing psychiatrists. Financial terms of the agreement were not disclosed.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=18942420&full=1)